Mitochondrial-targeting nitrooxy-doxorubicin: A new approach to overcome drug resistance

Molecular Pharmaceutics

Volumn 10, Issue 1, 2013, Pages 161-174

  Riganti, Chiara ^a,b   Rolando, Barbara ^b   Kopecka, Joanna ^a,b   Campia, Ivana ^a,b   Chegaev, Konstantin ^b   Lazzarato, Loretta ^b   Federico, Antonella ^b   Fruttero, Roberta ^b   Ghigo, Dario ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

ATP binding cassette transporters; doxorubicin; mitochondria; multidrug resistance; multifunctional drugs; nitric oxide

Indexed keywords

3 PHENYLSULFONYLFUROXAN DOXORUBICIN; ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; CASPASE 3; CASPASE 9; CYTOCHROME C; DOXORUBICIN; NITRIC OXIDE DONOR; NITROOXY DOXORUBICIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CITRIC ACID CYCLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESISTANCE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; MITOCHONDRIAL TARGETING SIGNAL; MITOCHONDRION; NITRATION; NITROSATIVE STRESS; OXIDATIVE STRESS; PRIORITY JOURNAL; SYNTHESIS;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CASPASE 3; CASPASE 9; CITRIC ACID CYCLE; CYTOCHROMES C; DNA TOPOISOMERASES, TYPE II; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ELECTRON TRANSPORT COMPLEX I; HT29 CELLS; HUMANS; K562 CELLS; MITOCHONDRIA; NITRIC OXIDE; NITRIC OXIDE DONORS; OXIDATIVE STRESS;

EID: 84872167461     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300311b     Document Type: Article

References (47)

1. Apetoh, L.; Mignot, G.; Panaretakis, T.; Kroemer, G.; Zitvogel, L. Immunogenicity of anthracyclines: Moving towards more personalized medicine Trends Mol. Med. 2008, 14, 141-151
2. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: Role of ATP-dependent transporters Nat. Rev. Cancer 2002, 2, 48-58
3. Takara, K.; Sakaeda, T.; Okumura, K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy Curr. Pharm. Des. 2006, 12, 273-286
4. Haouala, A.; Rumpold, H.; Untergasser, G.; Buclin, T.; Ris, H. B.; Widmer., N.; Decosterd, L,A. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors Drug Metab. Lett. 2010, 4, 114-119
5. Riganti, C.; Miraglia, E.; Viarisio, D.; Costamagna, C.; Pescarmona, G.; Ghigo, D.; Bosia, A. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res. 2005, 65, 516-525
6. De Boo, S.; Kopecka, J.; Brusa, D.; Gazzano, E.; Matera, L.; Ghigo, D.; Bosia, A.; Riganti, C. iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells Mol. Cancer 2009, 8, e108
7. Fruttero, R.; Crosetti, M.; Chegaev, K.; Guglielmo, S.; Gasco, A.; Berardi, F.; Niso, M.; Perrone, R.; Panaro, M. A.; Colabufo, N. A. Phenylsulfonylfuroxans as modulators of multidrug-resistance-associated protein-1 and P-glycoprotein J. Med. Chem. 2010, 53, 5467-575
8. Wink, D. A.; Mitchell, J. R. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic and cytoprotective mechanism of nitric oxide Free Radical Biol. Med. 1998, 25, 434-456
9. Nathan, C.; Xie, Q. W. Regulation of biosynthesis of nitric oxide J. Biol. Chem. 1994, 269, 13725-13728
10. Fitzpatrick, B.; Mehibel, M.; Cowen, R. L.; Stratford, I. J. iNOS as a therapeutic target for treatment of human tumors Nitric Oxide 2008, 19, 217-224
11. Singh, S.; Gupta, A. K. Nitric oxide: Role in tumour biology and iNOS/NO-based anticancer therapies Cancer Chemother. Pharmacol. 2011, 67, 1211-1224
12. Coulter, J. A.; McCarthy, H. O.; Xiang, J.; Roedl, W.; Wagner, E.; Robson, T.; Hirst, D. G. Nitric oxide-A novel therapeutic for cancer Nitric Oxide 2008, 19, 192-198
13. Engels, K.; Knauer, S. K.; Loibl, S.; Fetz, V.; Harter, P.; Schweitzer, A.; Fisseler-Eckhoff, A.; Kommoss, F.; Hanker, L.; Nekljudova, V.; Hermanns, I.; Kleinert, H.; Mann, W.; du Bois, A.; Stauber, R. H. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas Cancer Res. 2008, 68, 5159-5166
14. Huerta, S.; Chilka, S.; Bonavida, B. Nitric oxide donors: Novel cancer therapeutics Int. J. Oncol. 2008, 33, 909-927
15. Bonavida, B.; Khineche, S.; Huerta-Yepez, S.; Garbàn, H. Therapeutic potential of nitric oxide in cancer Drug Resist. Updates 2006, 9, 157-173
16. Muir, C. P.; Adams, M. A.; Graham, C. H. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells Breast Cancer Res. Treat. 2006, 96, 169-176
17. Frederiksen, L. J.; Sullivan, R.; Maxwell, L. R.; Macdonald-Goodfellow, S. K.; Adams, M. A.; Bennett, B. M.; Siemens, D. R.; Graham, C. H. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling Clin. Cancer Res. 2007, 13, 2199-2206
18. Chegaev, K.; Riganti, C.; Lazzarato, L.; Rolando, B.; Guglielmo, S.; Campia, I.; Fruttero, R.; Bosia, A.; Gasco, A. Nitric oxide donor-doxorubicin conjugates accumulate into doxorubicin resistant human colon cancer cells inducing cytotoxicity ACS Med. Chem. Lett. 2011, 2, 494-497
19. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
20. Riganti, C.; Orecchia, S.; Pescarmona, G.; Betta, P. G.; Ghigo, D.; Bosia, A. Statins revert doxorubicin resistance via nitric oxide in malignant mesotelioma Int. J. Cancer 2006, 119, 17-27
21. Okabe, M.; Szakàcs, G.; Reimers, M. A.; Suzuki, T.; Hall, M. D.; Abe, T.; Weinstein, J. N.; Gottesman, M. M. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters Mol. Cancer Ther. 2008, 7, 3081-3091
22. Campia, I.; Lussiana, C.; Pescarmona, G.; Ghigo, D.; Bosia, A.; Riganti, C. Geranylgeraniol prevents the cytotoxic effects of mevastatin in THP-1 cells, without decreasing the beneficial effects on cholesterol synthesis Br. J. Pharmacol. 2009, 158, 1777-1786
23. Wibom, R.; Hagenfeldt, L.; von Dobeln, U. Measurement of ATP production and respiratory chain enzyme activities in mitochondria isolated from small muscle biopsy samples Anal. Biochem. 2002, 311, 139-151
24. Riganti, C.; Gazzano, E.; Polimeni, M.; Costamagna, C.; Bosia, A.; Ghigo, D. Diphenyleneiodonium inhibits the cell reDOX metabolism and induces oxidative stress J. Biol. Chem. 2004, 279, 47726-47731
25. Ischiropoulos, H. Biological selectivity and functional aspects of protein tyrosine nitration Biochem. Biophys. Res. Commun. 2003, 305, 776-783
26. Russo, P.; Catassi, A.; Malacarne, D.; Margaritora, S.; Cesario, A.; Festi, L.; Mulé, A.; Ferri, L.; Granone, P. Tumor necrosis factor enhances sn38-mediated apoptosis in mesothelioma cells Cancer 2005, 103, 1503-1518
27. Sakai Kato, K.; Saito, E.; Ishikura, K.; Kawanishi, T. Analysis of intracellular doxorubicin and its metabolites by ultrahighperformance liquid chromatography J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2010, 878, 1466-1470
28. Rothweiler, F.; Michaelis, M.; Brauer, P.; Otte, J.; Weber, K.; Fehse, B.; Doerr, H. W.; Wiese, M.; Kreuter, J.; Al-Abed, Y.; Nicoletti, F.; Cinatl, J. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells Carcinogenesis 2012, 12, 1023-1030
29. Colabufo, N. A.; Contino, M.; Berardi, F.; Perrone, R.; Panaro, M. A.; Cianciulli, A.; Mitolo, V.; Azzariti, A.; Quatrale, A.; Paradiso, A. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents Toxicol. in Vitro 2011, 25, 222-230
30. Rao, C,V. Nitric oxide signaling in colon cancer chemoprevention Mutat. Res. 2004, 555, 107-119
31. Hagos, G. K.; Carroll, R. E.; Kouznetsova, T.; Li, Q.; Toader, V.; Fernandez, P. A.; Swanson, S. M.; Thatcher, G. R. J. Colon cancer chemoprevention by a novel NO chimera that shows anti-inflammatory and antiproliferative activity in vitro and in vivo Mol. Cancer Ther. 2007, 6, 2230-2239
32. Aldieri, E.; Bergandi, L.; Riganti, C.; Costamagna, C.; Bosia, A.; Ghigo, D. Doxorubicin induces an increase of nitric oxide synthesis in rat cardiac cells that is inhibited by iron supplementation Toxicol. Appl. Pharmacol. 2002, 185, 85-90
33. Evig, C. B.; Kelley, E. E.; Weydert, C. J.; Chu, Y.; Buettner, G. R.; Burns, C. P. Endogenous production and exogenous exposure to nitric oxide augment doxorubicin cytotoxicity for breast cancer cells but not cardiac myoblasts Nitric Oxide 2004, 10, 119-129
34. Zhu, S. G.; Kukreja, R. C.; Das, A.; Chen, Q.; Lesnefsky, E. J.; Xi, L. Dietary nitrate supplementation protects against doxorubicin-induced cardiomyopathy by improving mitochondrial function J. Am. Coll. Cardiol. 2011, 57, 2181-2189
35. Effenberger-Neidnicht, K.; Breyer, S.; Mahal, K.; Sasse, F.; Schobert, R. Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence Cancer Chemother. Pharmacol. 2012, 69, 85-90
36. Solazzo, M.; Fantappiè, O.; Lasagna, N.; Sassoli, C.; Nosi, D.; Mazzanti, R. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines Exp. Cell Res. 2006, 12, 4070-4078
37. Paterson, J. K.; Gottesman, M. M. P-glycoprotein is not present in mitochondrial membranes Exp. Cell Res. 2007, 313, 3100-3105
38. Solazzo, M.; Fantappiè, O.; D'Amico, M.; Sassoli, C.; Tani, A.; Cipriani, G.; Bogani, C.; Formigli, L.; Mazzanti, R. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines Cancer Res. 2009, 69, 7235-7242
39. Mayer, B.; Beretta, M. The enigma of nitroglycerin bioactivation and nitrate tolerance: news, views and troubles Br. J. Pharmacol. 2008, 155, 170-184
40. Paul, M. K.; Patkari, M.; Mukhopadhayay, A. P. Existence of a distinct concentration window governing daunorubicin-induced mammalian liver mitotoxicity-implication for determining therapeutic window Biochem. Pharmacol. 2007, 74, 821-830
41. Zhang, Y.; Li, R. J.; Ying, X.; Tian, W.; Yao, H. J.; Men, Y.; Yu, Y.; Zhang, L.; Ju, R. J.; Wang, X. X.; Zhou, J.; Chen, J. X.; Li, N.; Lu, W. L. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer Mol. Pharm. 2011, 8, 162-175
42. Bhattacharjee, A.; Majumdar, U.; Maity, D.; Subhra Sarkar, T.; Mohan Goswami, A.; Sahoo, R.; Ghosh, S. In vivo protein tyrosine nitration in S. cerevisiae: Identification of tyrosine-nitrated proteins in mitochondria Biochem. Biophys. Res. Commun. 2009, 388, 612-617
43. Sarti, P.; Arese, M.; Forte, E.; Giuffrè, A.; Mastronicola, D. Mitochondria and nitric oxide: Chemistry and pathophysiology Adv. Exp. Med. Biol. 2012, 942, 75-92
44. Sung, H. J.; Ma, W.; Wang, P.; Hynes, J.; O'Riordan, T. C.; Combs, C. A.; McCoy, J. P.; Bunz, F.; Kang, J. G.; Hwang, P. M. Mitochondrial respiration protects against oxygen-associated DNA damage Nat. Commun. 2010, 1, 5
45. Kim, P. K. M.; Kwon, Y. G.; Chung, H. T.; Kim, Y. M. Regulation of caspases by nitric oxide Ann. N.Y. Acad. Sci. 2002, 962, 42-52
46. Sonveaux, P.; Jordan, B. F.; Gallez, B.; Feron, O. Nitric oxide delivery to cancer: Why and how? Eur. J. Cancer 2009, 45, 1352-1369
47. Siemens, D. R.; Heaton, J. P.; Adams, M. A.; Kawakami, J.; Graham, C. H. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer Urology 2009, 74, 878-883